(ii)
All preparations and mixtures of such substances where such preparations and
mixtures are not expressly excluded.
This Schedule includes all substances subject to registration in terms of the Act and which are not listed
in any of the other Schedules.
Schedule 1
[Schedule 1 added by s. 36 of Act No. 65 of 1974, substituted by Government Notices No. R.420 of 7
March, 1975, No. R.2244 of 28 November, 1975, No. R.575 of 2 April, 1976 and No. R.2082 of 5
November, 1976, amended by Government Notices No. R.278 of 25 February, 1977, No. R.437 of 1
April, 1977, No. R.1194 of 1 July, 1977, No. R.1674 of 18 August, 1978 (as amended by Government
Notice No. R.2410 of 8 December, 1978), No. R.1926 of 31 August, 1979, No. R.2416 of 12 November,
1982 and No. R. 1289 of 14 June, 1985 (as amended by Government Notice No. 155 of 31 January,
1986), substituted by Government Notice No. 225 of 17 February, 1989, amended by Government
Notices No. R.2841 of 7 December, 1990, No. R.2169 of 6 September, 1991, No. R.348 of 5 March,
1993 and No. R.775 of 7 May, 1993, repealed, and subsequently re-inserted (after amendment), by s.
21 of Act No. 94 of 1991, amended by Government Notice No. R.1556 of 16 September, 1994, by
Government Notice No. R.673 of 12 May, 1995, by Government Notice No. R.42 of 19 January, 1996,
by Government Notice No. R.1496 of 13 September, 1996, by Government Notice No. R.1098 of 15
August, 1997, by Government Notice No. R.1099 of 15 August, 1997, by Government Notice
No. R.1203 of 15 October, 1999 and by Government Notice No. R.1077 of 3 November, 2000, repealed
by s. 27 of Act No. 90 of 1997 and inserted by Government Notice No. R.509 in Government Gazette
24727 of 10 April, 2003 with effect from 2 May, 2003.]
Wording of Sections
(a)
All substances referred to in this Schedule are excluded when specifically packed,
labeled and used for—
(i)
industrial purposes including the manufacture or compounding of consumer items or
products which have no pharmacological action or medicinal purpose; and
(ii)
analytical laboratory purposes.
(b)
All substances referred to in this Schedule include the following:
(i)
The salts and esters of such substances, where the existence of such salts and esters
is possible; and
(ii)
all preparations and mixtures of such substances where such preparations and
mixtures are not expressly excluded.
(c)
In terms of section 22A (4) (a) (v) of the Act, a practitioner, nurse or a person
registered under the Health Professions Act, 1974 (Act No. 56 of 1974) other than a medical practitioner
or dentist, may prescribe and supply to patients under their care, the Schedule 1 substances and
medicines provided for in the Annexures, only within their scope of practice and subject to the conditions
determined by the Medicines Control Council. The conditions and the Annexures will be published in the
Gazette.
Acetanilide and alkyl acetanilides.
Acetarsol, when intended for human vaginal use.
Acyclovir, when intended for application to the lips in the early treatment of recurrent herpes simplex
virus infections. (S4)
Anethole trithione.
Anticoagulants, when intended for application to the skin. (S4)
Antimalarials; chloroquine in combination with proguanil when intended specifically for malaria
prophylaxis. (S4)
Antimicrobial substances, namely bacitracin, gramicidin, polymyxin B and tyrothricin, when intended for
application to the skin, nares and external ear, as excluded from the conditions of Schedule 4. (S2, S4)
Antimony potassium tartrate and antimony sodium tartrate; substances, preparations and mixtures
containing 1,0 percent or more thereof.
Arsenic; substances, preparations and mixtures containing the equivalent of less than 0,01 percent of
arsenic trioxide. (S2)
Azelaic acid.
Belladonna alkaloids; when specifically intended for topical application (S2).
Benzethonium chloride, when intended for human vaginal use.
Benzydamine; preparations and mixtures containing—
(a)
3 per cent or less of benzydamine when intended for application to the skin;
(b)
0,15 per cent or less of benzydamine when intended for use as a mouth rinse or for
topical application in the mouth and throat: Provided that the total daily dose does not exceed 36 mg of
benzydamine. (S3)
Beta-aminopropylbenzene and beta-aminoisopropylbenzene as excluded from the conditions of
Schedule 5. (S5)
Bifonazole, when intended for application to the skin.
Bioallethrin.
Bitolterol.
Select target paragraph3
Connect to a paragraph
Connect to an entity
Disable highlights
Add to table of contents